Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
10 September 2024
| Name: | PSIRON LIMITED (PSX) (This company subsequently changed its name and is now VIRALYTICS LIMITED. You should refer to that name for Status.) | ||||||
| Date of Listing: | 15 October 1986 | ||||||
| Subsequent Names: |
| ||||||
| Former Names: |
|
Stock Exchange Status:
This company subsequently changed its name and is now VIRALYTICS LIMITED. You should refer to that name for Stock Exchange Status.Legal Status:
This company subsequently changed its name and is now VIRALYTICS LIMITED. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status:
This company subsequently changed its name and is now VIRALYTICS LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| VIRALYTICS LIMITED | 28/12/2006 | |
| PSIRON LIMITED | 17/08/2000 | 28/12/2006 |
| MEDICAL INNOVATIONS LIMITED | 17/08/2000 |
REGISTRY:
Link Market Services Brisbane
Level 21, 10 Eagle Street
Brisbane QLD 4000
Tel : +61 7 3320 2200 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail
name changed to Viralytics Limited | 28/12/2006 |
shares reinstated to quotation | 31/08/2006 |
CBio advises of the sale of its investment in BresaGen at a substantial profit and the placing of shares at $6 per share - Psiron owns 1.2 million shares in CBio Limited (cost price $1.00 per share) - this represents 4.7% of the share capital of the company | 14/08/2006 |
company clarifiies the cash flow numbers set out in the June Quarter Appendix 4c: "Staff costs (item 1.2a) for the quarter are shown as $142,000. Payments to directors and director related entities (item 1.24) are also shown as $142,000. Both of these numbers are correct, however should not be interpreted as being one and the same. The fact that the two figures are identical is purely coincidental. Simply, the composition of each of the numbers is different." | 09/08/2006 |
company releases a copy of a presentation and updates on studies and trials | 22/06/2006 |
company provides a general update covering matters in the notes below and advising that it intends to apply for requotation of its shares upon completion of the public offer | 09/06/2006 |
company announces the formal completion of its "first in man" Phase I trial in Malignant Melanoma | 05/06/2006 |
issues a prospectus and applies for the quotation of an additional 44m ordinary shares - via the prospectus the company seeks to raise approximately $6.6m via a non-renounceable rights issue ("Issue") of approximately 44,069,335 New Shares at a price of $0.15 each on the basis of one New Share for every four ordinary Shares held | 31/05/2006 |
Analytica Limited (ALT) has today announced the formation of a joint venture company in Hong Kong with Zhejiang Lingyang Medical Apparatus Company of Linhai China and J & J Stamina company of Taiwan - the joint venture company is expected shortly to sign a license agreement with Analytica Ltd to manufacture and distribute Analytica new constant flow auto burette and Analytica's retractable needle and syringe technologies - Psiron owns 26.7% of the share capital of Analytica Ltd | 16/05/2006 |
CBio Limited announces the completion of the first Phase 2a trial in Rheumatoid Arthritis in 23 patients - CBio is also concluding studies in both Phase II clinical trials in multiple sclerosis and psoriasis (Psiron owns 1.2 million shares in CBio Limited, 5% of the share capital of the company) | 09/05/2006 |
company advises it is working towards completing a private placement of up to 23.0 million new ordinary shares at 15 cents per share to raise up to $3.45 million - as of today's date, it has completed the placement of 12.0 million shares ($1.8 million) - based on commitments received, it is expected that additional shares will be placed shortly | 04/05/2006 |
quarterly cash flow report to 31 March 2006 shows a deficit at operating level of $1619k | 01/05/2006 |
company appoints AXIS Financial Group as financial advisers | 19/04/2006 |
the company has today been advised by DFS Equities that its current funding proposal has lapsed - the company is currently reviewing alternative funding proposals and is confident that a long term funding option for the company will be announced in the near future | 11/04/2006 |
shares suspended from quotation pending release of an announcement regarding the company's long term funding | 10/04/2006 |
name changed from Medical Innovations Limited | 17/08/2000 |
name changed to Viralytics Limited | 28/12/2006 |
shares reinstated to quotation | 31/08/2006 |
CBio advises of the sale of its investment in BresaGen at a substantial profit and the placing of shares at $6 per share - Psiron owns 1.2 million shares in CBio Limited (cost price $1.00 per share) - this represents 4.7% of the share capital of the company | 14/08/2006 |
company clarifiies the cash flow numbers set out in the June Quarter Appendix 4c: "Staff costs (item 1.2a) for the quarter are shown as $142,000. Payments to directors and director related entities (item 1.24) are also shown as $142,000. Both of these numbers are correct, however should not be interpreted as being one and the same. The fact that the two figures are identical is purely coincidental. Simply, the composition of each of the numbers is different." | 09/08/2006 |
company releases a copy of a presentation and updates on studies and trials | 22/06/2006 |
company provides a general update covering matters in the notes below and advising that it intends to apply for requotation of its shares upon completion of the public offer | 09/06/2006 |
company announces the formal completion of its "first in man" Phase I trial in Malignant Melanoma | 05/06/2006 |
issues a prospectus and applies for the quotation of an additional 44m ordinary shares - via the prospectus the company seeks to raise approximately $6.6m via a non-renounceable rights issue ("Issue") of approximately 44,069,335 New Shares at a price of $0.15 each on the basis of one New Share for every four ordinary Shares held | 31/05/2006 |
Analytica Limited (ALT) has today announced the formation of a joint venture company in Hong Kong with Zhejiang Lingyang Medical Apparatus Company of Linhai China and J & J Stamina company of Taiwan - the joint venture company is expected shortly to sign a license agreement with Analytica Ltd to manufacture and distribute Analytica new constant flow auto burette and Analytica's retractable needle and syringe technologies - Psiron owns 26.7% of the share capital of Analytica Ltd | 16/05/2006 |
CBio Limited announces the completion of the first Phase 2a trial in Rheumatoid Arthritis in 23 patients - CBio is also concluding studies in both Phase II clinical trials in multiple sclerosis and psoriasis (Psiron owns 1.2 million shares in CBio Limited, 5% of the share capital of the company) | 09/05/2006 |
company advises it is working towards completing a private placement of up to 23.0 million new ordinary shares at 15 cents per share to raise up to $3.45 million - as of today's date, it has completed the placement of 12.0 million shares ($1.8 million) - based on commitments received, it is expected that additional shares will be placed shortly | 04/05/2006 |
quarterly cash flow report to 31 March 2006 shows a deficit at operating level of $1619k | 01/05/2006 |
company appoints AXIS Financial Group as financial advisers | 19/04/2006 |
the company has today been advised by DFS Equities that its current funding proposal has lapsed - the company is currently reviewing alternative funding proposals and is confident that a long term funding option for the company will be announced in the near future | 11/04/2006 |
shares suspended from quotation pending release of an announcement regarding the company's long term funding | 10/04/2006 |
name changed from Medical Innovations Limited | 17/08/2000 |
Your browser may reflect a date of printing in American format.
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Bryan Dulhunty | Executive Chairman, Finance Director, Company Secretary | 10/04/2006 |
| Dennis Feeney | Director | |
| Darren Shafren | Director |
Date of first appointment, title may have changed.
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
